Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $27.8 million.

  • Regenxbio's Long-Term Investments rose 2046.91% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.8 million, marking a year-over-year increase of 2046.91%. This contributed to the annual value of $10.2 million for FY2024, which is 7381.34% down from last year.
  • As of Q3 2025, Regenxbio's Long-Term Investments stood at $27.8 million, which was up 2046.91% from $40.3 million recorded in Q2 2025.
  • Regenxbio's Long-Term Investments' 5-year high stood at $391.9 million during Q4 2021, with a 5-year trough of $4.9 million in Q1 2025.
  • Its 5-year average for Long-Term Investments is $138.3 million, with a median of $95.3 million in 2023.
  • As far as peak fluctuations go, Regenxbio's Long-Term Investments soared by 73724.71% in 2021, and later crashed by 8837.99% in 2025.
  • Regenxbio's Long-Term Investments (Quarter) stood at $391.9 million in 2021, then crashed by 48.82% to $200.6 million in 2022, then crashed by 80.62% to $38.9 million in 2023, then tumbled by 73.81% to $10.2 million in 2024, then soared by 173.48% to $27.8 million in 2025.
  • Its Long-Term Investments stands at $27.8 million for Q3 2025, versus $40.3 million for Q2 2025 and $4.9 million for Q1 2025.